In the treatment of inflammatory bowel disease, synthetic mucus gels can be used to deliver monoclonal antibodies without inducing broad immunosuppression.
Mindwalk identified TDP-43 antibodies that selectively target abnormal protein clumps linked to ALS and other diseases.
As Lindsey Vonn’s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the ...
This week's report explores the pharmaceutical industry’s evolution toward resilient, scalable systems that prioritize ...
A look at the clinical progress of anti-Aβ monoclonal antibodies and how precision delivery is shaping the next generation of ...
Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...
Kiniksa (KNSA) shifts from survival to growth as Arcalyst nears blockbuster sales and pipeline KPL-387 readouts loom—get the ...
A team from Würzburg has fundamentally changed our understanding of platelet biology. The researchers demonstrate that the ...
ADC conjugation, redefined. Explore a rapid 3-hour workflow that delivers precise, controlled antibody-drug conjugates for ...
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or ...
As of Friday, January 23, Coherus Oncology, Inc.’s CHRS share price has surged by 21.70%, which has investors questioning if ...
Berger has participated in meetings (lectures, advisory boards, consultations) sponsored and compensated by pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results